Javier J. Lepe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Javier J. Lepe has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Annenelie Bota
University of California, Irvine 1 Department of Experimental Pathology and Laboratory Medicine Irvine, California
16 shared publications - Naomi Lomeli
Department of Neurology, University of California Irvine, Irvine, CA, USA
14 shared publications - Bhaskar C. Das
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14215, USA
12 shared publications - Chokkalingam Parthiban
Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, West Bengal, India
12 shared publications - Jennifer D. Tran
University of California, Irvine 1 Department of Experimental Pathology and Laboratory Medicine Irvine, California
12 shared publications - Sasmita Das
The State University of New York (SUNY) 6 Division of Drug and Biotherapeutic Discovery, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo Buffalo, New York
12 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 57
A novel rat model of ovarian cancer and cisplatin chemotherapy-related cognitive impairment
- 22 September 2026
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 57
Open AccessA novel rat model of ovarian cancer and cisplatin chemotherapy-related cognitive impairment
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
MAGMAS is differentially expressed in newly diagnosed vs. recurrent GBM patient-derived tumor specimens and TMZ-resistant glioma lines. A,PAM16 mRNA expression in IDH1 wild-type newly diagnosed and recurrent GBM tumor samples from the CGGA and TCGA datasets. Two-tailed unpaired t test statistical analyses was performed. B, Correlation between PAM16 and MGMT mRNA expression in primary GBM patient tumor samples. Pearson correlation, CGGA, R = 0.7869, P < 0.0001; TCGA, R = 0.2773, P < 0.0001. qPCR analysis of PAM16 in (C) U-251 MG S, TR, and OTR and (D) D-54 MG S, TR, and OTR lines. U-251 MG S and T98 cells treated with (E) 1,000 μmol/L TMZ, (F) 30 mmol/L DCA (U-251 MG S), or 34 mmol/L DCA (T98G). RNA was collected at 0 days (vehicle control) and 1-, 2-, and 3-day time points, and qPCR analysis of PAM16 was performed. One-way ANOVA, post hoc Tukey, P < 0.05. qPCR analysis of PAM16 expression in (G) U-251 MG S, (H) D-54 MG S, and (I) T98G cells cultured in GSC media. Cells were collected at 9 and 30 days, and PAM16 expression was compared with cells grown in serum control media. One-way ANOVA, post hoc Tukey, multiple comparisons, P < 0.05. J, Flow cytometry analysis of CD133 expression of D-54 MG cells at 0, 9, and 30 days cultured in GSC media for dedifferentiation. On 30 days of dedifferentiation, (K) U-251 MG and (L) D-54 MG were collected and treated with graded doses of TMZ for 5 days; cell viability was assessed by MTT. All data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
MAGMAS is differentially expressed in newly diagnosed vs. recurrent GBM patient-derived tumor specimens and TMZ-resistant glioma lines. A,PAM16 mRNA expression in IDH1 wild-type newly diagnosed and recurrent GBM tumor samples from the CGGA and TCGA datasets. Two-tailed unpaired t test statistical analyses was performed. B, Correlation between PAM16 and MGMT mRNA expression in primary GBM patient tumor samples. Pearson correlation, CGGA, R = 0.7869, P < 0.0001; TCGA, R = 0.2773, P < 0.0001. qPCR analysis of PAM16 in (C) U-251 MG S, TR, and OTR and (D) D-54 MG S, TR, and OTR lines. U-251 MG S and T98 cells treated with (E) 1,000 μmol/L TMZ, (F) 30 mmol/L DCA (U-251 MG S), or 34 mmol/L DCA (T98G). RNA was collected at 0 days (vehicle control) and 1-, 2-, and 3-day time points, and qPCR analysis of PAM16 was performed. One-way ANOVA, post hoc Tukey, P < 0.05. qPCR analysis of PAM16 expression in (G) U-251 MG S, (H) D-54 MG S, and (I) T98G cells cultured in GSC media. Cells were collected at 9 and 30 days, and PAM16 expression was compared with cells grown in serum control media. One-way ANOVA, post hoc Tukey, multiple comparisons, P < 0.05. J, Flow cytometry analysis of CD133 expression of D-54 MG cells at 0, 9, and 30 days cultured in GSC media for dedifferentiation. On 30 days of dedifferentiation, (K) U-251 MG and (L) D-54 MG were collected and treated with graded doses of TMZ for 5 days; cell viability was assessed by MTT. All data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
IC50 values and HSA scores for BT9 and TMZ.
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
IC50 values and HSA scores for BT9 and TMZ.
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Data from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Glioblastoma (GBM, isocitrate dehydrogenase wild-type grade 4 astrocytoma) is the most aggressive and common brain tumor, characterized by increased proliferation, invasiveness, mitochondrial-dependent changes, and necrosis. GBM recurrence is universal despite the standard-of-care treatment with maximal surgical resection, radiation, and temozolomide (TMZ). Most patients relapse 6 to 9 months following initial diagnosis, and the median survival after recurrence is less than a year. Therefore, effective therapeutic strategies are needed to overcome glioma resistance mechanisms and improve long-term outcomes for patients with GBM. Mitochondria-associated granulocyte macrophage colony-stimulating factor molecule (MAGMAS, PAM16) is a nuclear-encoded mitochondrial protein subunit of the translocase of the inner membrane 23 complex that functions as an essential regulator of protein trafficking into the mitochondrial matrix. We previously demonstrated that MAGMAS is overexpressed in GBM and that the small-molecule MAGMAS inhibitor BT9 reduces mitochondrial respiration and is cytotoxic to glioma cells in vitro. In this study, we investigated the role of MAGMAS in GBM biology and the effects of MAGMAS inhibition on TMZ-resistant glioma lines and patient-derived glioma stem-like cells. We observed elevated PAM16 levels in recurrent GBM, chemoresistant glioma cells, and during metabolic switching processes. Concurrent treatment with BT9 and TMZ significantly increased cell death compared with either drug alone in all glioma lines, irrespective of their TMZ resistance status. Additionally, GBM cells constitutively expressing shPAM16 became sensitized to TMZ both in vitro and in vivo in an intracranial xenograft model. Our findings suggest that targeting MAGMAS holds promise as a novel, effective therapeutic strategy for GBM.Significance:This study finds a link between mitochondrial protein MAGMAS and chemotherapy resistance in glioma central nervous system cancers. These findings can help improve our understanding of how mitochondria play an important role in chemotherapy resistance mechanisms - highlighting MAGMAS as a target to help enhance the efficacy of TMZ in chemotherapy resistance cells
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Glioblastoma (GBM, isocitrate dehydrogenase wild-type grade 4 astrocytoma) is the most aggressive and common brain tumor, characterized by increased proliferation, invasiveness, mitochondrial-dependent changes, and necrosis. GBM recurrence is universal despite the standard-of-care treatment with maximal surgical resection, radiation, and temozolomide (TMZ). Most patients relapse 6 to 9 months following initial diagnosis, and the median survival after recurrence is less than a year. Therefore, effective therapeutic strategies are needed to overcome glioma resistance mechanisms and improve long-term outcomes for patients with GBM. Mitochondria-associated granulocyte macrophage colony-stimulating factor molecule (MAGMAS, PAM16) is a nuclear-encoded mitochondrial protein subunit of the translocase of the inner membrane 23 complex that functions as an essential regulator of protein trafficking into the mitochondrial matrix. We previously demonstrated that MAGMAS is overexpressed in GBM and that the small-molecule MAGMAS inhibitor BT9 reduces mitochondrial respiration and is cytotoxic to glioma cells in vitro. In this study, we investigated the role of MAGMAS in GBM biology and the effects of MAGMAS inhibition on TMZ-resistant glioma lines and patient-derived glioma stem-like cells. We observed elevated PAM16 levels in recurrent GBM, chemoresistant glioma cells, and during metabolic switching processes. Concurrent treatment with BT9 and TMZ significantly increased cell death compared with either drug alone in all glioma lines, irrespective of their TMZ resistance status. Additionally, GBM cells constitutively expressing shPAM16 became sensitized to TMZ both in vitro and in vivo in an intracranial xenograft model. Our findings suggest that targeting MAGMAS holds promise as a novel, effective therapeutic strategy for GBM.Significance:This study finds a link between mitochondrial protein MAGMAS and chemotherapy resistance in glioma central nervous system cancers. These findings can help improve our understanding of how mitochondria play an important role in chemotherapy resistance mechanisms - highlighting MAGMAS as a target to help enhance the efficacy of TMZ in chemotherapy resistance cells
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Table S1. Cell Line MGMT Methylation Status
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Table S1. Cell Line MGMT Methylation Status
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
MAGMAS knockdown in GBM cells increases sensitivity to TMZ, radiation, and TTFs. A, Western blot analysis of MAGMAS protein levels in mitochondrial lysates from U-251 MG and T98G cells lentiviral transduced with either scramble control or shPAM16. TIM23 was used as a loading control for each sample. B,MGMT mRNA expression was quantified by qPCR in U-251 MG, T98G, and G12 scramble and shPAM16 cell lines. C, Whole cell lysates harvested from T98G scramble and sh1 cells probed with anti-MGMT (bottom bands) and Β-actin (top bands) as a loading control. Membrane is a duplicate of Supplementary Fig. S3D. Only T98G cells had detectable MGMT at the protein level which is highlighted here. D,PAM16 knockdown U-251 MG cells were treated with 24 μmol/L TMZ for 5 days, and the percent of PI+ cells were determined by flow cytometry (n = 4). E, Cellular ROS measured from U-251 MG, T98G, and G12 PAM16 knockdown cells with stained with CellROX and analyzed by flow cytometry (n = 4). Statistical analyses were done with unpaired t test, mean ± SD. F, Representative images of clonogenic assay plates and (G) quantification of surviving fraction of U-251 MG and T98G scramble control and PAM16 knockdown cells exposed to 0 to 6 Gy of radiation. Colonies were counted manually. Statistical analyses were performed using the mixed-effects model, Sidak multiple comparisons test, P < 0.05, mean with ± SD. MFI, median fluorescence intensity. H, U-251 MG and T98G scramble control and PAM16 knockdown cells were exposed to 200 Hz TTFs for 3 days. Cell viability was assessed by quantifying the percent of PI+ cells using flow cytometry. Significance was determined using a two-way ANOVA, Sidak multiple comparisons test, P < 0.05. I, Timeline and experimental design of the G12-Luc orthotopic xenograft model. Scramble + vehicle: n = 5; Scramble + TMZ; n = 5; Sh1 + vehicle: n = 5; Sh1 + TMZ: n = 5. J, Kaplan–Meier curve depicting survival of PAM16 knockdown transduced G12-Luc orthotopic xenograft mouse model. K, Summary of bioluminescence imaging of mice from all treatment groups (photons/s) from different time points of the study. L, The change in body weights of mice was measured at different time points throughout the study. Log-rank P values, Scrbl. vehicle vs. Sh1 vehicle P = 0.0017, Scrbl. vehicle vs. Scrbl. TMZ P = 0.0017, Scrbl. vehicle vs. Sh1 TMZ P = 0.0017, Scrbl. TMZ vs. Sh1 vehicle P = 0.0021, Scrbl. TMZ vs. Sh1 TMZ P= 0.0018, and Sh1 vehicle vs. Sh1 TMZ P = 0.0021. Data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. [I, Created in BioRender. Lepe, J. (2026) https://BioRender.com/wvy3h4p].
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
MAGMAS knockdown in GBM cells increases sensitivity to TMZ, radiation, and TTFs. A, Western blot analysis of MAGMAS protein levels in mitochondrial lysates from U-251 MG and T98G cells lentiviral transduced with either scramble control or shPAM16. TIM23 was used as a loading control for each sample. B,MGMT mRNA expression was quantified by qPCR in U-251 MG, T98G, and G12 scramble and shPAM16 cell lines. C, Whole cell lysates harvested from T98G scramble and sh1 cells probed with anti-MGMT (bottom bands) and Β-actin (top bands) as a loading control. Membrane is a duplicate of Supplementary Fig. S3D. Only T98G cells had detectable MGMT at the protein level which is highlighted here. D,PAM16 knockdown U-251 MG cells were treated with 24 μmol/L TMZ for 5 days, and the percent of PI+ cells were determined by flow cytometry (n = 4). E, Cellular ROS measured from U-251 MG, T98G, and G12 PAM16 knockdown cells with stained with CellROX and analyzed by flow cytometry (n = 4). Statistical analyses were done with unpaired t test, mean ± SD. F, Representative images of clonogenic assay plates and (G) quantification of surviving fraction of U-251 MG and T98G scramble control and PAM16 knockdown cells exposed to 0 to 6 Gy of radiation. Colonies were counted manually. Statistical analyses were performed using the mixed-effects model, Sidak multiple comparisons test, P < 0.05, mean with ± SD. MFI, median fluorescence intensity. H, U-251 MG and T98G scramble control and PAM16 knockdown cells were exposed to 200 Hz TTFs for 3 days. Cell viability was assessed by quantifying the percent of PI+ cells using flow cytometry. Significance was determined using a two-way ANOVA, Sidak multiple comparisons test, P < 0.05. I, Timeline and experimental design of the G12-Luc orthotopic xenograft model. Scramble + vehicle: n = 5; Scramble + TMZ; n = 5; Sh1 + vehicle: n = 5; Sh1 + TMZ: n = 5. J, Kaplan–Meier curve depicting survival of PAM16 knockdown transduced G12-Luc orthotopic xenograft mouse model. K, Summary of bioluminescence imaging of mice from all treatment groups (photons/s) from different time points of the study. L, The change in body weights of mice was measured at different time points throughout the study. Log-rank P values, Scrbl. vehicle vs. Sh1 vehicle P = 0.0017, Scrbl. vehicle vs. Scrbl. TMZ P = 0.0017, Scrbl. vehicle vs. Sh1 TMZ P = 0.0017, Scrbl. TMZ vs. Sh1 vehicle P = 0.0021, Scrbl. TMZ vs. Sh1 TMZ P= 0.0018, and Sh1 vehicle vs. Sh1 TMZ P = 0.0021. Data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. [I, Created in BioRender. Lepe, J. (2026) https://BioRender.com/wvy3h4p].
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Figure S2. Combinatorial BT9 + TMZ treatment of human primary cell line in orthotopic mouse model.
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Figure S2. Combinatorial BT9 + TMZ treatment of human primary cell line in orthotopic mouse model.
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Figure S1. TMZ resistance in GBM cells and proteomic changes after MAGMAS inhibition.
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Figure S1. TMZ resistance in GBM cells and proteomic changes after MAGMAS inhibition.
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Pharmacologic MAGMAS inhibition by BT9 reduces protein trafficking into the mitochondria and increases oxidative stress in glioma lines U-251 MG, T98G, and D-54 MG. A, U-251 MG and D-54 MG were treated with 10 μmol/L BT9 for 24 hours. Mitochondrial lysates were collected, and protein levels of LONP1, ACO2, cytochrome C, COXIV, and TIM23 were assessed by Western blot. TIM23 was used as a loading control. B, U-251 MG and T98G cells were treated with 5 μmol/L BT9 and 2.5 mmol/L of NAC for 24 hours and probed with MitoSOX Red. The median fluorescence intensity (MFI) was determined by flow cytometry (n = 3 technical replicates). C, U-251 MG cells were exposed to 5.6 μmol/L BT9 ± 2.5 mmol/L NAC for 3 days. Cells were then stained with Annexin V/PI and analyzed by flow cytometry to assess early and late apoptosis. Early and late apoptosis events observed for the vehicle were 13%, 5.9% for the NAC control, 30.7% for the BT9-treated cells, and 13.6% for the BT9 and NAC-treated cells. Data representative of one experiment. Data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 9 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models
Pharmacologic MAGMAS inhibition by BT9 reduces protein trafficking into the mitochondria and increases oxidative stress in glioma lines U-251 MG, T98G, and D-54 MG. A, U-251 MG and D-54 MG were treated with 10 μmol/L BT9 for 24 hours. Mitochondrial lysates were collected, and protein levels of LONP1, ACO2, cytochrome C, COXIV, and TIM23 were assessed by Western blot. TIM23 was used as a loading control. B, U-251 MG and T98G cells were treated with 5 μmol/L BT9 and 2.5 mmol/L of NAC for 24 hours and probed with MitoSOX Red. The median fluorescence intensity (MFI) was determined by flow cytometry (n = 3 technical replicates). C, U-251 MG cells were exposed to 5.6 μmol/L BT9 ± 2.5 mmol/L NAC for 3 days. Cells were then stained with Annexin V/PI and analyzed by flow cytometry to assess early and late apoptosis. Early and late apoptosis events observed for the vehicle were 13%, 5.9% for the NAC control, 30.7% for the BT9-treated cells, and 13.6% for the BT9 and NAC-treated cells. Data representative of one experiment. Data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.